{"id":"https://openalex.org/W2138023988","doi":"https://doi.org/10.1158/1535-7163.mct-14-0580","title":"Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy","display_name":"Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy","alternate_titles":[],"publication_year":2015,"publication_date":"2015-02-01","ids":{"openalex":"https://openalex.org/W2138023988","doi":"https://doi.org/10.1158/1535-7163.mct-14-0580","mag":"2138023988","pmid":"https://pubmed.ncbi.nlm.nih.gov/25512619"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-14-0580","doi":"https://doi.org/10.1158/1535-7163.mct-14-0580","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-14-0580","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2138023988"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061753604","display_name":"Netai C. Singha","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088034","display_name":"Halozyme Therapeutics (United States)","ror":"https://ror.org/001x5ea44","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088034"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Netai C. Singha","raw_affiliation_strings":["1Halozyme Therapeutics, Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Halozyme Therapeutics, Inc., San Diego, California","institution_ids":["https://openalex.org/I4210088034"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033029873","display_name":"Tara Nekoroski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088034","display_name":"Halozyme Therapeutics (United States)","ror":"https://ror.org/001x5ea44","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088034"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Tara Nekoroski","raw_affiliation_strings":["1Halozyme Therapeutics, Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Halozyme Therapeutics, Inc., San Diego, California","institution_ids":["https://openalex.org/I4210088034"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101953835","display_name":"Chun\u2010Mei Zhao","orcid":"https://orcid.org/0009-0001-3559-3884","observed_orcids":["https://orcid.org/0009-0001-3559-3884"]},"institutions":[{"id":"https://openalex.org/I4210088034","display_name":"Halozyme Therapeutics (United States)","ror":"https://ror.org/001x5ea44","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088034"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Chunmei Zhao","raw_affiliation_strings":["1Halozyme Therapeutics, Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Halozyme Therapeutics, Inc., San Diego, California","institution_ids":["https://openalex.org/I4210088034"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069988060","display_name":"Rebecca C. Symons","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088034","display_name":"Halozyme Therapeutics (United States)","ror":"https://ror.org/001x5ea44","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088034"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Rebecca Symons","raw_affiliation_strings":["1Halozyme Therapeutics, Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Halozyme Therapeutics, Inc., San Diego, California","institution_ids":["https://openalex.org/I4210088034"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068765890","display_name":"Ping Jiang","orcid":"https://orcid.org/0000-0001-5123-5705","observed_orcids":["https://orcid.org/0000-0001-5123-5705"]},"institutions":[{"id":"https://openalex.org/I4210088034","display_name":"Halozyme Therapeutics (United States)","ror":"https://ror.org/001x5ea44","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088034"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ping Jiang","raw_affiliation_strings":["1Halozyme Therapeutics, Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Halozyme Therapeutics, Inc., San Diego, California","institution_ids":["https://openalex.org/I4210088034"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Gregory I. Frost","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gregory I. Frost","raw_affiliation_strings":["2Intrexon Corporation, San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Intrexon Corporation, San Diego, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100569830","display_name":"Zhongdong Huang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088034","display_name":"Halozyme Therapeutics (United States)","ror":"https://ror.org/001x5ea44","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088034"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Zhongdong Huang","raw_affiliation_strings":["1Halozyme Therapeutics, Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Halozyme Therapeutics, Inc., San Diego, California","institution_ids":["https://openalex.org/I4210088034"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5023977680","display_name":"Harold Michael Shepard","orcid":"https://orcid.org/0000-0003-1868-9179","observed_orcids":["https://orcid.org/0000-0003-1868-9179"]},"institutions":[{"id":"https://openalex.org/I4210088034","display_name":"Halozyme Therapeutics (United States)","ror":"https://ror.org/001x5ea44","country_code":"US","type":"company","lineage":["https://openalex.org/I4210088034"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"H. Michael Shepard","raw_affiliation_strings":["1Halozyme Therapeutics, Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Halozyme Therapeutics, Inc., San Diego, California","institution_ids":["https://openalex.org/I4210088034"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.9902,"has_fulltext":false,"cited_by_count":150,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.95459385,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":100},"biblio":{"volume":"14","issue":"2","first_page":"523","last_page":"532"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11131","display_name":"Proteoglycans and glycosaminoglycans research","score":0.9868000149726868,"subfield":{"id":"https://openalex.org/subfields/1307","display_name":"Cell Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11131","display_name":"Proteoglycans and glycosaminoglycans research","score":0.9868000149726868,"subfield":{"id":"https://openalex.org/subfields/1307","display_name":"Cell Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10343","display_name":"Hydrogels: synthesis, properties, applications","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hyaluronic-acid","display_name":"hyaluronic acid","score":0.9760000109672546},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.9480000138282776},{"id":"https://openalex.org/keywords/pegph20","display_name":"PEGPH20","score":0.8500000238418579},{"id":"https://openalex.org/keywords/hyaluronidase","display_name":"hyaluronidase","score":0.9829999804496765},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.9829999804496765},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.9369999766349792},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9679999947547913},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.40400001406669617}],"concepts":[{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.7118831276893616},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5150055885314941},{"id":"https://openalex.org/C2777843201","wikidata":"https://www.wikidata.org/wiki/Q17163357","display_name":"Monoclonal antibody therapy","level":4,"score":0.5025453567504883},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.48350289463996887},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.42498916387557983},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4201945662498474},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3732183575630188},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.17788755893707275}],"mesh":[{"descriptor_ui":"D000068878","descriptor_name":"Trastuzumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000920","descriptor_name":"Antibody-Dependent Cell Cytotoxicity","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D002450","descriptor_name":"Cell Communication","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D005109","descriptor_name":"Extracellular Matrix","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006820","descriptor_name":"Hyaluronic Acid","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D006820","descriptor_name":"Hyaluronic Acid","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D007694","descriptor_name":"Killer Cells, Natural","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1158/1535-7163.mct-14-0580","doi":"https://doi.org/10.1158/1535-7163.mct-14-0580","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-14-0580","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:25512619","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25512619","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":50,"referenced_works":["https://openalex.org/W1507435475","https://openalex.org/W1526048511","https://openalex.org/W1543772239","https://openalex.org/W1710368740","https://openalex.org/W1965962344","https://openalex.org/W2004490932","https://openalex.org/W2013689372","https://openalex.org/W2016732129","https://openalex.org/W2021737426","https://openalex.org/W2023681515","https://openalex.org/W2026515229","https://openalex.org/W2030864157","https://openalex.org/W2036545145","https://openalex.org/W2044360617","https://openalex.org/W2047900555","https://openalex.org/W2052926310","https://openalex.org/W2055091294","https://openalex.org/W2057623977","https://openalex.org/W2058085176","https://openalex.org/W2058475776","https://openalex.org/W2058692868","https://openalex.org/W2068071851","https://openalex.org/W2069377326","https://openalex.org/W2071717470","https://openalex.org/W2083982805","https://openalex.org/W2088128469","https://openalex.org/W2089668087","https://openalex.org/W2094092091","https://openalex.org/W2098983864","https://openalex.org/W2100527196","https://openalex.org/W2105865292","https://openalex.org/W2113320375","https://openalex.org/W2119957267","https://openalex.org/W2120178047","https://openalex.org/W2128402413","https://openalex.org/W2130464657","https://openalex.org/W2133205391","https://openalex.org/W2134561732","https://openalex.org/W2134989772","https://openalex.org/W2139966914","https://openalex.org/W2148794649","https://openalex.org/W2156106286","https://openalex.org/W2156701124","https://openalex.org/W2157824687","https://openalex.org/W2158303916","https://openalex.org/W2161744213","https://openalex.org/W2167864307","https://openalex.org/W2168467781","https://openalex.org/W2172265576","https://openalex.org/W2403623613"],"related_works":["https://openalex.org/W2223118781","https://openalex.org/W2169001577","https://openalex.org/W2328488226","https://openalex.org/W2176993652","https://openalex.org/W4393093893","https://openalex.org/W2885747242","https://openalex.org/W2954322358","https://openalex.org/W2324041301","https://openalex.org/W2886179532","https://openalex.org/W3083291269"],"abstract_inverted_index":{"Despite":[0],"tremendous":[1],"progress":[2],"in":[3,40,54,73,89,156,170,186,201,210,218,236],"cancer":[4],"immunotherapy":[5],"for":[6,247],"solid":[7,42],"tumors,":[8,83,199],"clinical":[9],"success":[10],"of":[11,30,36,70,88,100,108,159,226],"monoclonal":[12],"antibody":[13,77],"(mAb)":[14],"therapy":[15,246],"is":[16,46],"often":[17],"limited":[18],"by":[19,136,161],"poorly":[20],"understood":[21],"mechanisms":[22],"associated":[23,47,66],"with":[24,48,67,238],"the":[25,37,74,132],"tumor":[26,43,138,149,177,207],"microenvironment":[27],"(TME).":[28],"Accumulation":[29],"hyaluronan":[31],"(HA),":[32],"a":[33,63,85,163,222],"major":[34],"component":[35],"TME,":[38],"occurs":[39],"many":[41],"types,":[44],"and":[45,51,78,105,111,118,151,179,193,204,229,232],"poor":[49],"prognosis":[50],"treatment":[52,190,235],"resistance":[53,91],"multiple":[55],"malignancies.":[56],"In":[57],"this":[58],"study,":[59],"we":[60],"describe":[61],"that":[62,97,120,131,215,233],"physical":[64],"barrier":[65,223],"high":[68],"levels":[69],"HA":[71,160],"(HA(high))":[72],"TME":[75],"restricts":[76],"immune":[79,145],"cell":[80,114,146,173,195],"access":[81,147,174,196,225],"to":[82,92,126,148,175,197],"suggesting":[84],"novel":[86],"mechanism":[87],"vivo":[90,219],"mAb":[93,127,228],"therapy.":[94,128],"We":[95,129],"determined":[96],"approximately":[98,106],"60%":[99],"HER2(3+)":[101],"primary":[102],"breast":[103],"tumors":[104,122],"40%":[107],"EGFR(+)":[109],"head":[110],"neck":[112],"squamous":[113],"carcinomas":[115],"are":[116],"HA(high),":[117],"hypothesized":[119],"HA(high)":[121,137,176,198,216,248],"may":[123,220,241],"be":[124,242],"refractory":[125],"found":[130],"pericellular":[133],"matrix":[134,217],"produced":[135],"cells":[139,150],"inhibited":[140],"both":[141,227],"natural":[142],"killer":[143],"(NK)":[144],"antibody-dependent":[152],"cell-mediated":[153,206],"cytotoxicity":[154],"(ADCC)":[155],"vitro.":[157,187],"Depletion":[158],"PEGPH20,":[162],"pegylated":[164],"recombinant":[165],"human":[166],"PH20":[167],"hyaluronidase,":[168],"resulted":[169],"increased":[171],"NK":[172,194,205,230],"cells,":[178,231],"greatly":[180],"enhanced":[181,191,202],"trastuzumab-":[182,203],"or":[183],"cetuximab-dependent":[184],"ADCC":[185],"Furthermore,":[188],"PEGPH20":[189,234],"trastuzumab":[192],"resulting":[200],"growth":[208],"inhibition":[209],"vivo.":[211],"These":[212],"results":[213],"suggest":[214],"form":[221],"inhibiting":[224],"combination":[237],"anticancer":[239],"mAbs":[240],"an":[243],"effective":[244],"adjunctive":[245],"tumors.":[249]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2138023988","counts_by_year":[{"year":2026,"cited_by_count":12},{"year":2025,"cited_by_count":13},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":12},{"year":2022,"cited_by_count":17},{"year":2021,"cited_by_count":23},{"year":2020,"cited_by_count":16},{"year":2019,"cited_by_count":11},{"year":2018,"cited_by_count":14},{"year":2017,"cited_by_count":10},{"year":2016,"cited_by_count":12},{"year":2015,"cited_by_count":5}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
